Pharmacokinetics and Pharmacodynamics of JNJ-55920839, an Antibody Targeting Interferon  α/ω, in Healthy Subjects and Subjects with Mild-to-Moderate Systemic Lupus Erythematosus

ConclusionPharmacokinetic and pharmacodynamic analyses of the data from this study demonstrated that there was biphasic disposition in both healthy subjects and subjects with SLE, CL was faster in subjects with SLE, and increases in total IFN α/ω levels were observed in both healthy subjects and subjects with SLE after treatment with JNJ-55920839, thus further development is supported.The study is registered at ClinicalTrials.gov NCT02609789.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research